DiaSorin SpA
MIL:DIA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
83.3
110.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
DiaSorin SpA
DiaSorin SpA
Total Current Liabilities
DiaSorin SpA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DiaSorin SpA
MIL:DIA
|
Total Current Liabilities
€266.4m
|
CAGR 3-Years
20%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
El En SpA
MIL:ELN
|
Total Current Liabilities
€311.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
DiaSorin SpA
Glance View
DiaSorin SpA is a prominent Italian diagnostic solutions provider that has carved a niche in the healthcare industry. Founded in 1968, the company specializes in developing and manufacturing innovative diagnostic tests that facilitate disease detection, monitoring, and prevention. With a robust portfolio that ranges from immunodiagnostics to molecular diagnostics, DiaSorin has made significant strides in addressing urgent healthcare needs. The company operates globally, serving hospitals and laboratories across numerous countries, and has established a strong commitment to research and development. This focus not only enhances their product offerings but also positions them as a key player in rapidly evolving sectors like infectious disease testing, oncology, and autoimmune disorders. For investors, DiaSorin presents an intriguing opportunity rooted in its strategic growth initiatives and resilience amid market challenges. The company's strong track record of revenue growth and profitability, coupled with its agile response to emerging health crises—such as the COVID-19 pandemic—highlights its operational efficiency and adaptability. Furthermore, with an ongoing emphasis on expanding its product lines and seeking partnerships to drive innovation, DiaSorin is well positioned to capitalize on the increasing demand for advanced diagnostic solutions. As healthcare continues to evolve with technological advances and personalized medicine, DiaSorin’s capabilities and strong market presence make it a compelling consideration for investors looking for sustainable growth in the life sciences sector.
See Also
What is DiaSorin SpA's Total Current Liabilities?
Total Current Liabilities
266.4m
EUR
Based on the financial report for Jun 30, 2024, DiaSorin SpA's Total Current Liabilities amounts to 266.4m EUR.
What is DiaSorin SpA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
11%
Over the last year, the Total Current Liabilities growth was -6%. The average annual Total Current Liabilities growth rates for DiaSorin SpA have been 20% over the past three years , 11% over the past five years .
You don't have any saved screeners yet
